Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 2, 2015, Pages 223-233

  Weisberg, Daniel F ^a   Gordon, Kirsha S ^b   Barry, Declan T ^c   Becker, William C ^a,b   Crystal, Stephen ^d   Edelman, Eva J ^a,e   Gaither, Julie ^e   Gordon, Adam J ^f,g   Goulet, Joseph ^b,c   Kerns, Robert D ^b,c   Moore, Brent A ^b,c,e   Tate, Janet ^a,b   Justice, Amy C ^a,b,e   Fiellin, David A ^a,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Departments of Psychiatry   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

benzodiazepines; HIV; opioid analgesics; pharmacoepidemiology; polypharmacy

Indexed keywords

ALPRAZOLAM; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; ESTAZOLAM; FLURAZEPAM; LORAZEPAM; MIDAZOLAM; OPIATE; OXAZEPAM; TEMAZEPAM; TRIAZOLAM; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RISK FACTOR; COHORT ANALYSIS; HIV INFECTIONS; MIDDLE AGED; SURVIVAL;

ADULT; ANALGESICS, OPIOID; ANTI-RETROVIRAL AGENTS; BENZODIAZEPINES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84929878265     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000591     Document Type: Article

References (77)

1. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67: 26-36.
2. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7:225-235.
3. Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17:173-179.
4. Braden JB, Fan MY, Edlund MJ, et al. Trends in use of opioids by noncancer pain type 2000-2005 among ArkansasMedicaid and HealthCare enrollees: results from the TROUP study. J Pain. 2008;9:1026-1035.
5. Pletcher MJ, Kertesz SG, Kohn MA, et al. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299:70-78.
6. Becker WC, Gordon K, Edelman EJ, Kerns R, Crystal S, Dziura J, Fiellin L, Gordon A, Goulet J, Justice A, Fiellin D. Trends in opioid analgesic receipt among patients with and without HIV. Society of General Internal Medicine National Meeting, April 2013, Denver CO, April 2013.
7. Hawkins EJ, Malte CA, Imel ZE, et al. Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003-2010. Drug Alcohol Depend. 2012;124:154-161.
8. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.
9. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363:1981-1985.
10. Uhlenhuth EH, Balter MB, Ban TA, et al. Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997. Eur Neuropsychopharmacol. 1999;9(suppl 6):S393-S398.
11. Reinhold JA, Mandos LA, Rickels K, et al. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12: 2457-2467.
12. Offidani E, Guidi J, Tomba E, et al. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: A systematic review and meta-analysis. Psychother and Psychosom. 2013;82:355-362.
13. Charlson F, Degenhardt L, McLaren J, et al. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf. 2009;18:93-103.
14. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta-analysis of RCTs. J Gen Intern Med. 2007;22:1335-1350.
15. Amarasuriya UK, Myles PR, Sanders RD. Long-term benzodiazepine use and mortality: are we doing the right studies? Curr Drug Saf. 2012;7: 367-371.
16. Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012;344:e2502.
17. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170: 1968-1976.
18. Gomes T, Juurlink DN, Dhalla IA, et al. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011;5: e13-22.
19. Huang AR, Mallet L, Rochefort CM, et al. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012; 29:359-376.
20. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170:1979-1986.
21. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: A populationbased case-control study. J Am Geriatr Soc. 2011;59:1899-1907.
22. Li L, Setoguchi S, Cabral H, et al. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013;273:511-526.
23. Wasan AD, Butler SF, Budman SH, et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23:307-315.
24. Sullivan MD, Edlund MJ, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006;166:2087-2093.
25. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8-18.
26. Vogel M, Knopfli B, Schmid O, et al. Treatment or "high": benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38:2477-2484.
27. Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30:613-628.
28. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728.
29. Hansen L, Penko J, Guzman D, et al. Aberrant behaviors with prescription opioids and problem drug use history in a communitybased cohort of HIV-infected individuals. J Pain Symptom Manage 2011;42:893-902.
30. Edelman JE, Gordon K, Akgun K, Gibert C, Lo Re III V, McNicholl I, Rimland D, Skanderson M, Tate J, Womack J, Wyatt C, Justice AC. HIV+ individuals on ART are at risk of polypharmacy: more medication increases mortality. ID Week 2013; October 2-6, 2013; San Francisco, CA; Abstract 76. https://idsa.confex.com/idsa/2013/webprogram/ Paper42415.html. Accessed April 1, 2015.
31. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149:981-983.
32. Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012;36:318-324.
33. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737-743.
34. Freiberg MS, Chang CC, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4:425-432.
35. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care. 2006;44:S25-S30.
36. Smith MW, Joseph GJ. Pharmacy data in the VA health care system. Med Care Res Rrev. 2003;60:92S-123S.
37. Centers for Medicare and Medicaid Services. ICD-9 Provider and diagnostic codes. 2011. Available at: https://http://www.cms.gov/ Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html. Accessed July 20, 2013.
38. Edelman EJ, Gordon K, Becker WC, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28:82-90.
39. Korff MV, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain. 2008;24:521-527.
40. Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12:462-468.
41. Fisher SG, Weber L, Goldberg J, et al. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol. 1995;141:242-250.
42. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789-1795.
43. Seale JP, Boltri JM, Shellenberger S, et al. Primary care validation of a single screening question for drinkers. J Stud Alcohol. 2006;67:778-784.
44. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: A North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62: 149-163.
45. Akgun KM, Tate JP, Pisani M, et al. Medical ICU admission diagnoses and outcomes in human immunodeficiency virus-infected and virusuninfected veterans in the combination antiretroviral era. Crit Care Med. 2013;41:1458-1467.
46. Erlandson KM, Allshouse AA, Jankowski C. Prospective comparison of three functional assessments with the Veteran's Aging Cohort Study index in virologically suppressed HIV-infected adults. 2nd International Workshop on HIV and Aging, Baltimore, MD, October 2011.
47. Womack JA, Goulet JL, Gibert C, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013; 56:1498-1504.
48. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin infect dis. 2012;54:984-994.
49. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
50. Freemantle N, Marston L, Walters K, et al. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.
51. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
52. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156.
53. Austin PC. The use of propensity score methods with survival or time-toevent outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242-1258.
54. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med. 2010;152: 85-92.
55. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305:1315-1321.
56. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147-159.
57. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444-459.
58. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116-127.
59. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: A systematic review. Addiction. 2013;108:688-698.
60. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300: 2613-2620.
61. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171:686-691.
62. Jann M, Kennedy WK, Lopez G. Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract. 2014;27:5-16.
63. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010;7:152-160.
64. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict. 2010;19:4-16.
65. Green TC, McGowan SK, Yokell MA, et al. HIV infection and risk of overdose: A systematic review and meta-analysis. AIDS. 2012;26: 403-417.
66. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105-S120.
67. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med. 2010;25:310-315.
68. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952-1960.
69. Saunders KW, Von Korff M, Campbell CI, et al. Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors. J Pain. 2012;13:266-275.
70. Parsells Kelly J, Cook SF, Kaufman DW, et al. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008; 138:507-513.
71. Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28:173-186.
72. Azar MM, Springer SA, Meyer JP, et al. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178-193.
73. Cargiulo T. Understanding the health impact of alcohol dependence. Am J Health-syst pharm. 2007;64:S5-S11.
74. Yang HW, Simoni-Wastila L, Zuckerman IH, et al. Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions. Psychiatr Serv. 2008;59:384-391.
75. McGinnis KA, Fine MJ, Sharma RK, et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003;93:1728-1733.
76. Sinnott PL, Siroka AM, Shane AC, et al. Identifying neck and back pain in administrative data: defining the right cohort. Spine (Phila Pa 1976) 2012;37:860-874.
77. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241-249.